Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;49(2):71-2.
doi: 10.5483/bmbrep.2016.49.2.010.

Brain somatic mutations in MTOR leading to focal cortical dysplasia

Jae Seok Lim  1 , Jeong Ho Lee  1
Affiliations

Brain somatic mutations in MTOR leading to focal cortical dysplasia

Jae Seok Lim et al. BMB Rep. 2016 Feb.

Abstract

Focal cortical dysplasia type II (FCDII) is a focal malformation of the developing cerebral cortex and the major cause of intractable epilepsy. However, since the molecular genetic etiology of FCD has remained enigmatic, the effective therapeutic target for this condition has remained poorly understood. Our recent study on FCD utilizing various deep sequencing platforms identified somatic mutations in MTOR (existing as low as 1% allelic frequency) only in the affected brain tissues. We observed that these mutations induced hyperactivation of the mTOR kinase. In addition, focal cortical expression of mutant MTOR using in utero electroporation in mice, recapitulated the neuropathological features of FCDII, such as migration defect, cytomegalic neuron and spontaneous seizures. Furthermore, seizures and dysmorphic neurons were rescued by the administration of mTOR inhibitor, rapamycin. This study provides the first evidence that brain somatic activating mutations in MTOR cause FCD, and suggests the potential drug target for intractable epilepsy in FCD patients. [BMB Reports 2016; 49(2): 71-72].

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.. Schematic presentation of the experimental design. Deep whole exome sequencing (WES) was performed in four FCDII patients, and the raw sequencing data were analyzed to discover an alternative allele. Overlapping mutations in both Virmid and MuTect algorithms were selected as candidate single nucleotide variants (SNVs). Subsequently, we performed deep sequencing of the MTOR gene with various sequencing platforms in a large FCDII cohort comprising an additional 73 patients. Finally, the validated MTOR mutations were subjected to in vitro and in vivo functional analysis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

Substances